参麦注射液和复方丹参注射液治疗急性脑梗死的Meta分析

目的利用Meta分析方法对参麦注射液和复方丹参注射液相互对照治疗急性脑梗死的临床研究进行合并分析，评价两种药物治疗急性脑梗死的临床效果。方法检索1990-2007年在生物医学期刊上发表的参麦注射液和复方丹参注射液对照治疗急性脑梗死的临床研究文献，将符合纳入标准的试验纳入本次研究，采用Review Mananer4．2软件对其进行ICMeta（Intra-ChinaMeta）分析。结果共纳入文献6篇，X^2分布显示具有同质性（P〉0．05），故采用固定效应模型进行统计分析，得到合并后的比值比OR（95%CI）4．73（2．61-8．56），参麦注射液和复方丹参注射液治疗急性脑梗死总有效率具有极显著性差异（P〈0．01）。结论我国近十多年来用参麦注射液和丹参注射液治疗急性脑梗死的文献，采用随机对照比例较低，随机的质量和可信度较差；盲法未被采用；还存在组间基线均衡性的比较、对照措施的合理性、结局指标的选择等方面问题。本研究采用Meta分析进行统计学处理，结果显示参麦注射液治疗急性脑梗死的疗效优于复方丹参注射液。

Meta analysis of the treatment for acute cerebral infarction with Shenmai injection and compound salvia miltiorrhiza injection

Objective It is to analyze the clinical contrast study of Shenmai injection （SI） and compound salvia miltior-rhiza injection （CSMI） on acute cerebral infarction by Meta analysis method, to evaluate the clinical effect of the drugs above on the disease. Methods References about treatment comparing study of SI and CSMI on cerebral infarction which published on biomedical science periodicals between 1990-2007 were retrieved, and the ones which were accord with the criterion were chosen and analyzed by Using ICMeta（ Intra-ChinaMeta）-analysis of Review Mananer 4.2. Results The resuks showed that there were 6 literatures which corresponded with the criterion were homogenous by test for heterogeneity （ P 〉 0.05）. Changeless benefit model statistics and analysis showed that the OR（95 % CI） was 4.73 （2.61 - 8.56）. The difference in total effective rate of SI and CSMI was significant（ P 〈 0.01）. Conclusion： At present, the documents of SI and CSMI treatment for cerebral infarction in China had many problems. For example, the researches seldom use random and control methods, random dividing has a bad quality and reliability, blind methods are not adopted. The problems including compare base- line balance, reasonable contrast measure, choice of final target also exist. The result from the Meter statistic analysis indi-cates SI has a better effect on acute cerebral infarction than CSMI.